Revista nº 815

Dexametasona y COVID | Martínez-Zaldívar Moreno M, et al. 38 Actual Med.2022;107(815):34- 38 11. Callejas Rubio JL, Luna Del Castillo JD, de la Hera Fer- nández J, Guirao Arrabal E, Colmenero Ruiz M, Ortego Centeno N. Effectiveness of corticoid pulses in patients with cytokine storm syndrome induced by SARS-CoV-2 infection. Med Clin (Engl Ed). 2020 Aug 28;155(4):159- 161. DOI: 10.1016/j.medcle.2020.07.002. 12. Hyrich KL, Machado PM. Rheumatic disease and CO- VID-19: epidemiology and outcomes. Nat Rev Rheuma- tol. 2021 Feb;17(2):71-72. DOI: 10.1038/s41584-020- 00562-2. 13. Gianfrancesco M, Hyrich KL, Al-Adely S, Carmona L, Da- nila MI, Gossec L, Izadi Z, et al; COVID-19 Global Rheu- matology Alliance. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumato- logy Alliance physician-reported registry. Ann Rheum Dis. 2020 Jul;79(7):859-866. DOI: 10.1136/annrheum- dis-2020-217871. 14. Ram-Mohan N, Kim D, Zudock EJ, Hashemi MM, Tjandra KC, Rogers AJ, et al. . SARS-CoV-2 RNAae- mia predicts clinical deterioration and extrapulmo- nary complications from COVID-19. medRxiv [Pre- print]. 2020 Dec 22:2020.12.19.20248561. DOI: 10.1101/2020.12.19.20248561. Si desea citar nuestro artículo: Martínez-Zaldívar Moreno M, Aguilera Maestre E, Espinosa Bar- ta P, Navarro Ortiz N, Callejas Rubio JL. Dexametasona en pa- cientes no hospitalizados con infeccion por SARS-Cov-2. Actual Med.2022;107(815):34- 38. DOI: 10.15568/am.2022.815. or04